Schroders is a multinational asset management company established in 1804 and headquartered in London, England. The firm specializes in managing a diverse range of assets, including equities, fixed income, multi-asset strategies, and alternatives, for institutional and retail investors, financial institutions, and high-net-worth clients globally. With a portfolio valued at approximately £300 billion, Schroders aims to create long-term value aligned with the interests of its clients. The company employs over 3,500 professionals across 37 offices in 27 countries, ensuring close proximity to the markets and clients it serves. In addition to asset management, Schroders offers wealth management services that encompass portfolio management, wealth planning, banking, and treasury services for high-net-worth individuals, family offices, and charities. With a history spanning over 200 years, Schroders emphasizes long-term thinking in its investment approach and client relationship management.
Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing novel treatments for advanced liver diseases. Founded in 2019, the company aims to address conditions such as liver fibrosis, cirrhosis, and liver cancer, particularly targeting Claudin-1 positive tumors and organ fibrosis. Alentis employs a research platform that utilizes clinically relevant readouts and single-cell RNA sequencing of patient liver tissues, enabling the development of effective therapies to combat fibrosis and reverse the progression of these diseases. Through its innovative approach, Alentis Therapeutics seeks to improve outcomes for patients suffering from severe liver-related health issues.
Cera Care Limited specializes in providing home care services for elderly individuals, including elderly care, palliative care, respite care, post-discharge care, dementia care, and private nursing services. Established in 2015 and based in London, the company has expanded its reach across various regions in the United Kingdom, such as Hertfordshire, Bedfordshire, and Oxfordshire. Cera employs a digital platform that features a matching algorithm and automated scheduling systems, allowing for efficient home care arrangements within 24 hours. This innovative approach reduces overhead costs compared to traditional care providers, enabling Cera to offer competitive rates while paying its caregivers above the industry average. As a result, the company attracts experienced and well-trained carers committed to delivering high-quality care tailored to the individual needs and preferences of their clients. Cera Care Limited was formerly known as Golden Era Club Ltd before rebranding in July 2018.
Forteus is an asset management firm specializing in blockchain technology and digital assets. The company offers a variety of investment strategies that leverage research, technology, and risk management. Its services include customized portfolios managed by external managers, yield generation, actively managed thematic portfolios, and tokenization. By providing these solutions, Forteus enables investors to engage with trends and investment strategies within the digital asset sector.
Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G Protein-Coupled Receptors (GPCRs), which are key drug targets in various diseases. The company specializes in developing treatments for Central Nervous System (CNS) disorders and cancer. Utilizing its proprietary DTect-All technology, Domain Therapeutics identifies both orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs), which are not discoverable through conventional methods. This innovative approach allows the company to address challenging GPCRs, including orphan and peptidic receptors. Founded in 2001, the company was previously known as Faust Pharmaceuticals SA before rebranding in December 2008.
Redcliffe LifetechRedcliffe Lifesciences specializes in reproductive health testing, rare diseases, and cancer genetic diagnostics. The company offers a wide range of advanced products and services for healthcare companies, research institutions, and other public and private partnerships, such as testing using molecular and gene-based diagnostics, therapeutic molecules and advanced therapies, next-generation sequencing, and all bioinformatics services.
Healthy Workers B.V. engages in the development of B2B solutions to create healthy working environment for organizations. The company's products include WELLBEING-SCAN and an employer dashboard that enable employers to measure, analyze, and take measures to improve the well-being of their employees. The company engages in providing consultancy services on productivity, stress, engagement, well-being, and stressors in the workplace. The company was founded in 2016 and is headquartered in Amsterdam, the Netherlands.
IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor.
Eikon Therapeutics is a biopharmaceutical company focused on developing innovative treatments for chronic and life-threatening diseases. Founded in 2019 and based in Hayward, California, the company utilizes advanced super-resolution microscopy technology to conduct live-cell and single-molecule imaging. This cutting-edge approach allows for real-time, molecular-resolution measurements of protein movement within living cells, enabling the identification of previously intractable drug targets. By directly measuring the interactions between chemical compounds and individual proteins in a cellular environment, Eikon Therapeutics aims to unlock new avenues for drug discovery and address complex health challenges.
Ambys Medicines, Inc. is a biotechnology company based in Redwood City, California, founded in 2016. The company focuses on discovering and developing innovative therapies for severe liver diseases. Its approach includes gene therapy, drug therapy, and cell therapy, aiming to restore liver function, halt the progression of liver disease, and address the serious complications associated with liver failure. Through its research and development efforts, Ambys Medicines seeks to significantly improve the quality of life for individuals affected by liver-related health issues.
Operator of a renewable energy company intended to develop, build, own and operate solar PV and wind assets. The company develops biogas and biomethane units that generate power and gas from organic waste.
AgroStar is a leading AgTech start-up in India dedicated to supporting farmers by offering a comprehensive range of agricultural solutions. Through its technology platform, AgroStar provides agronomy advice, services, and agricultural input products that aim to enhance farmers' productivity and income. The platform leverages extensive data and agronomy expertise to deliver tailored solutions to Indian farmers. Operating primarily in Gujarat, Maharashtra, and Rajasthan, AgroStar serves over 500,000 farmers, who can access solutions for their entire crop life-cycle via a simple missed call or through its highly-rated Android app. The company's offerings include expert advice, personalized content, and agricultural inputs such as seeds and nutrients. Over the next five years, AgroStar plans to expand its services, providing farmers with a wider range of inputs delivered to their doorsteps, superior agronomy guidance, and improved access to market linkages and credit.
Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer treatments that target DNA damage response (DDR) pathways. Founded in 2015, the company aims to create first-in-class therapies that selectively kill cancer cells by exploiting the mechanisms involved in DNA repair. Its product pipeline features several promising candidates, including DNA polymerase theta (Polθ) and an in-licensed program targeting a novel DDR protein. Artios collaborates with Cancer Research Technology and leading researchers in the field to advance its development efforts. The company's leadership comprises experts with extensive experience in DDR drug discovery, and it has garnered investment from notable entities, including SV Life Sciences and AbbVie Ventures.
Provider of commercial mortgage services to the real estate sector based in Sydney, Australia. the company specializes in loan origination, loan management, and funds management across commercial, retail, industrial real estate, and construction.
CeQur SA focuses on creating innovative insulin delivery systems aimed at improving the management of type 2 diabetes. The company is developing the CeQur Insulin Infuser, a discreet and user-friendly device that allows patients to receive both basal and bolus insulin over a three-day period. This technology helps facilitate intensive insulin therapy, offering individuals flexibility and alleviating the need for multiple daily injections. Founded in January 2008 as a spin-off from Danfoss A/S, CeQur is headquartered in Montreux, Switzerland, with additional operations in Nordborg, Denmark, and Marlborough, Massachusetts. Through its products, CeQur seeks to enhance the quality of life for diabetes patients by simplifying insulin delivery and promoting better adherence to therapy.
Graphcore Limited, a hardware systems company develops intelligent processing units. It offers IPU-Accelerator cards, which can be plugged into a server to accelerate machine-learning applications; and IPU-Appliance products that provide enhanced performance to deliver inference systems supporting various users or provide faster training. Graphcore Limited was incorporated in 2016 and is based in Bristol, United Kingdom with additional locations in Palo Alto, California; London, United Kingdom; Oslo, Norway; and Beijing, China.
Pamfleet Group is a real estate investment firm established in 2000 and based in Hong Kong, with additional offices in Singapore. The firm focuses on investing in residential and commercial properties, particularly targeting B-Grade commercial real estate that offers potential for repositioning or redevelopment. As an independent and privately owned advisor, Pamfleet specializes in identifying underperforming assets and executing strategies to enhance their value. The firm provides a range of services, including real estate asset management and investment advisory. With a management team experienced in the Asia-Pacific real estate market since 1990, Pamfleet is recognized for its active value-creation approach and innovative transaction strategies. In July 2020, the firm underwent a significant change when Schroders took a majority stake, leading to its rebranding as Schroders Pamfleet.
BlueOrchard Finance, established in 2001 and headquartered in Zurich, Switzerland, is a prominent asset manager specializing in impact investing, particularly in microfinance. The firm focuses on providing debt financing to microfinance institutions and invests in growth capital for mid-sized companies in emerging markets. With a commitment to social and environmental impact, BlueOrchard targets sectors such as renewable energy, energy efficiency, and waste management. The firm has disbursed over USD 2 billion in loans globally and aims to enhance financial inclusion and improve living standards for underserved populations. BlueOrchard operates additional offices in locations including Cambodia, Georgia, Peru, and Kenya, and offers a variety of investment solutions including credit, private equity, and sustainable infrastructure.
Blue Asset Management is a full-service investment manager based in Munich, Germany, specializing in commercial real estate. The company manages over 80 commercial properties for institutional investors, with a total market value of approximately 1.5 billion euros. Blue Asset Management prioritizes integrity, professionalism, and reliability, focusing on building long-term, trusted relationships with clients and business partners. Its approach emphasizes active communication and transparency, fostering cooperative relationships within the real estate sector.
Thirdrock Group - Wealth management business
Acquisition in 2019
Thirdrock Group - Wealth management business provides wealth management services.
Qwil Messenger is a communication software designed to facilitate secure and compliant B2B messaging. The platform features a single chat application that enables businesses to create a GDPR-compliant communication channel for interactions with staff, clients, and partners. It allows users to initiate virtual meetings with a single click and store files securely in one location. Qwil Messenger supports integration with 200 endpoints, enabling automation as business needs evolve. The application is designed for multiple firms and their clients, providing a branded space that is fully controlled and coordinated by each organization. Its proprietary technology allows for rapid deployment across various jurisdictions, ensuring scalability and compliance in communication.
WeInvest is a Singapore-based online platform established in 2013 that facilitates individual investors in exploring various investment opportunities, including real estate, mutual funds, and deposits. The platform provides users with investment ideas, helps them identify suitable products, and enables tracking of their investment portfolios. Additionally, it offers connections to prospective brokers and advisors. WeInvest operates as a digital wealth management service, aiming to make investing more accessible and transparent. It provides aggregation services and features such as robo-advisory and goal-based investing, empowering banks, wealth managers, insurance companies, and independent financial advisors to better engage with their clients, plan investments, and analyze portfolio performance.
Algonquin SA, based in Brussels, Belgium, specializes in the investment, ownership, operation, and franchising of hotels across Europe. Founded in 1998, the company currently manages 43 hotel assets, offering over 7,500 rooms with a combined value of €1.8 billion. Approximately half of these properties operate under Algonquin's own brands or renowned international franchises, while the remainder is managed through agreements with major international operators. What distinguishes Algonquin is its dual role as both an investor and an operator, enabling active involvement in hotel operations. This includes oversight of daily management functions, human resources, sales and marketing strategies, and regulatory compliance, as well as real estate management through in-house project expertise and capital expenditure programs. As a result, Algonquin has attracted investments from institutional investors, family offices, and private equity firms into various dedicated investment vehicles.
Adveq, founded in 1997 and now known as Schroder Adveq, is a prominent asset manager specializing in private equity and real asset investments on a global scale. Headquartered in Zurich, the firm provides tailored investment solutions that enable clients to access targeted segments of private markets. Adveq has invested in over 400 funds, consistently delivering strong returns across various economic cycles. Its clientele primarily consists of institutional investors, including pension funds, insurance companies, family offices, and other financial institutions from Europe, North America, and the Asia-Pacific region. The firm has cultivated long-term relationships with many investors, earning a reputation as a trusted partner in private market investing. Adveq operates offices in major financial centers, including Frankfurt, London, New York, Beijing, Shanghai, and Hong Kong, and maintains an agent relationship in Sydney.
Nutmeg Saving and Investment Limited, commonly known as Nutmeg, is an online investment management firm based in London, United Kingdom. Established in 2011, Nutmeg provides clients with portfolio management services, helping them make informed investment decisions related to equities, corporate bonds, gilts, and gold. The company specializes in various investment vehicles, including ISAs and pensions, and is recognized as the first wealth manager in the UK to offer a six-year performance track record. Nutmeg aims to simplify money management for individuals through its intelligent and straightforward approach to investing.
Benchmark Capital, established in 2015, focuses on enhancing the growth and success of firms in the financial services sector. The company offers a comprehensive suite of digital wealth management solutions that equip financial advisers with insights, integrated tools, and investment services to enhance their client offerings. By uniting various components of the fragmented industry, Benchmark Capital provides best-in-class technology solutions and discretionary platforms. This approach delivers competitive advantages to over 120 prominent national and regional firms, positioning them for greater success in the marketplace.
CeQur SA focuses on creating innovative insulin delivery systems aimed at improving the management of type 2 diabetes. The company is developing the CeQur Insulin Infuser, a discreet and user-friendly device that allows patients to receive both basal and bolus insulin over a three-day period. This technology helps facilitate intensive insulin therapy, offering individuals flexibility and alleviating the need for multiple daily injections. Founded in January 2008 as a spin-off from Danfoss A/S, CeQur is headquartered in Montreux, Switzerland, with additional operations in Nordborg, Denmark, and Marlborough, Massachusetts. Through its products, CeQur seeks to enhance the quality of life for diabetes patients by simplifying insulin delivery and promoting better adherence to therapy.
Nutmeg Saving and Investment Limited, commonly known as Nutmeg, is an online investment management firm based in London, United Kingdom. Established in 2011, Nutmeg provides clients with portfolio management services, helping them make informed investment decisions related to equities, corporate bonds, gilts, and gold. The company specializes in various investment vehicles, including ISAs and pensions, and is recognized as the first wealth manager in the UK to offer a six-year performance track record. Nutmeg aims to simplify money management for individuals through its intelligent and straightforward approach to investing.
Cazenove Capital is a leading provider of personalised wealth management services to private clients, family offices, trusts, companies and pension plans. As a long-established wealth manager with an absolute focus on preserving and growing their clients’ wealth, what matters most to their clients, matters most to them. Private individuals, family offices, trusts, businesses and pension plans all rely on them to provide them with bespoke, discretionary and advisory investment services. Skilled in investment management, wealth planning and banking services – they also offer discretionary fund management to external advisers and their clients, and they are a leading charity fund manager in the UK. Their experience of navigating complex markets and adapting to change, helps them balance risk and reward. The investment expertise they call upon as part of a truly global asset manager, combined with their long-standing experience of advising clients, is what sets them apart.
STW Fixed Income Management Ltd. is an employee-owned investment manager based in Santa Barbara, California, managing approximately $11 billion in assets. Founded in 1977, the firm specializes in fixed income investment management for a diverse clientele, including pensions, foundations, endowments, family offices, insurance companies, and various trusts. STW focuses on creating separate client-oriented portfolios, primarily investing in the public fixed income markets of the United States. The firm emphasizes sectors such as technology, particularly in technical infrastructure and software development, and exclusively invests in investment-grade fixed income value securities. Utilizing both fundamental and quantitative analysis, STW aims to optimize portfolio performance while adhering to its clients' specific investment objectives.
GeoSentric's GyPSii is the market-leading mobile digital lifestyle application and geo-mobility social networking platform: connecting people, places and communities across networks and devices, with patented technologies for the transfer and publishing of location based information between mobile devices. Based in Salo, Finland and Amsterdam, The Netherlands, GeoSentric operates offices in North America, Europe and Asia Pacific. GeoSentric is listed on the Nordic Exchange (NASDAQ OMX: GEO1V)).
CeQur SA focuses on creating innovative insulin delivery systems aimed at improving the management of type 2 diabetes. The company is developing the CeQur Insulin Infuser, a discreet and user-friendly device that allows patients to receive both basal and bolus insulin over a three-day period. This technology helps facilitate intensive insulin therapy, offering individuals flexibility and alleviating the need for multiple daily injections. Founded in January 2008 as a spin-off from Danfoss A/S, CeQur is headquartered in Montreux, Switzerland, with additional operations in Nordborg, Denmark, and Marlborough, Massachusetts. Through its products, CeQur seeks to enhance the quality of life for diabetes patients by simplifying insulin delivery and promoting better adherence to therapy.
GeoSentric's GyPSii is the market-leading mobile digital lifestyle application and geo-mobility social networking platform: connecting people, places and communities across networks and devices, with patented technologies for the transfer and publishing of location based information between mobile devices. Based in Salo, Finland and Amsterdam, The Netherlands, GeoSentric operates offices in North America, Europe and Asia Pacific. GeoSentric is listed on the Nordic Exchange (NASDAQ OMX: GEO1V)).
Orthomimetics
Series A in 2006
Orthomimetics was founded in 2005 as a spin-out from the University of Cambridge and the Massachusetts Institute of Technology (MIT). Its products are based on a leading collagen biomaterials platform for the production of scaffolds for cartilage, meniscus, ligament and tendon repair. Orthomimetics’ flagship product, Chondromimetic™, is an off-the-shelf, resorbable implant for the minimally invasive repair of small osteochondral (cartilage and underlying bone) defects. The product has received European market approval (CE-Mark approval) and is close to entering the European market. Small osteochondral defects represent an important medical need that is currently not covered by TiGenix’ products. Chondromimetic™ forms an excellent fit with TiGenix’ lead product, ChondroCelect®, since both products target the same customer base in complementary indications.
Newfinance Capital
Acquisition in 2006
Newfinance Capital is a London-based funds of hedge funds manager.
Square Enix is a prominent developer and publisher of interactive entertainment, renowned for its diverse portfolio of video game franchises. Founded in 1989 and headquartered in El Segundo, California, the company produces a wide array of titles across various platforms, including mobile, console, and PC. Notable franchises include Final Fantasy, Dragon Quest, Hitman, Deus Ex, and Kingdom Hearts. In addition to video games, Square Enix engages in the publication of online games, mobile entertainment, music, and DVDs. The company also offers PlayOnline, a cross-platform online community, and multiplayer online role-playing games. With a strong presence in both the North American and European markets, Square Enix continues to influence the global gaming landscape through its innovative content and distribution strategies.
CellZome is a pharmaceutical company based in Heidelberg, Baden-Württemberg, that specializes in the discovery, development, and commercialization of kinase-targeted drugs aimed at treating inflammatory diseases. Founded in 2000, the company focuses on creating a pipeline of kinase inhibitors that act on inflammatory mediators, offering oral therapeutic options for conditions such as rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis, and asthma.
iCollector, founded in 1997 and based in Port Coquitlam, Canada, operates a comprehensive online auction platform that connects auctioneers with buyers worldwide. The platform features a diverse range of auction items, including coins, vintage collectibles, gaming memorabilia, collectible firearms, movie props, original set costumes, and unique jewelry. With over 1,000 auction house clients, iCollector offers pay-per-use access to its platform, allowing clients to list items in a catalog format aligned with their physical auctions. Bidders can register for free, place and modify bids, and participate in live auctions in real time. iCollector has conducted over 10,000 auctions, utilizing a robust database to provide valuable insights and support to both bidders and auction houses. The company also offers marketing assistance, auction house support, and integration of payment and shipping functions to streamline operations. iCollector shares resources with its sister platform, LiveAuctionWorld, and is part of a brand group that includes LiveAuctionGroup, which specializes in custom software solutions for the auction industry.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.